1. Home
  2. ENTA vs OPRT Comparison

ENTA vs OPRT Comparison

Compare ENTA & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$11.37

Market Cap

377.5M

Sector

Health Care

ML Signal

HOLD

OPRT

Oportun Financial Corporation

HOLD

Current Price

$8.87

Market Cap

421.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
OPRT
Founded
1995
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
377.5M
421.7M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
ENTA
OPRT
Price
$11.37
$8.87
Analyst Decision
Strong Buy
Buy
Analyst Count
6
4
Target Price
★ $21.83
$11.50
AVG Volume (30 Days)
242.2K
★ 704.4K
Earning Date
11-16-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
★ 127.18
EPS
N/A
★ 0.22
Revenue
$102,814,000.00
★ $956,685,000.00
Revenue This Year
N/A
$30.33
Revenue Next Year
N/A
$5.23
P/E Ratio
★ N/A
$41.20
Revenue Growth
★ 16.48
N/A
52 Week Low
$10.20
$4.03
52 Week High
$17.15
$9.35

Technical Indicators

Market Signals
Indicator
ENTA
OPRT
Relative Strength Index (RSI) 43.19 59.80
Support Level $10.86 $7.12
Resistance Level $13.95 N/A
Average True Range (ATR) 0.64 0.36
MACD -0.08 0.02
Stochastic Oscillator 28.14 68.38

Price Performance

Historical Comparison
ENTA
OPRT

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

Share on Social Networks: